Introduction
Wasting conditions associated with various inflammatory diseases have been known since ancient time. In Greece, Hippocrates precisely described the core pathogenesis of cachexia, wherein "the flesh is consumed and becomes water" and considered cachexia as a sign of death. [1] In ancient China, a similar wasting condition, limpness, was described in an old textbook and reported to be induced by chronic inflammatory diseases in various organs. [2] According to the account, the patient's muscles in the trunk and lower limbs had atrophy, which resulted in difficulties in standing up or walking. The unfavorable impact of cachexia on functional prognosis has been more emphasized than that on survival prognosis. In the Middle East, Avicenna, a medieval Arab scholar, also stated the importance of avoiding a cachectic condition for the maintenance of healthy and active life, especially in the elderly population. [3] Despite this long history of cachexia in humans, there is limited understanding of such condition. This may be partial because cachexia is a functional disorder and its primary cause is macroscopically invisible. Based on recent advances in medicine, the pathophysiology of cachexia is known to involve multiple organs including skeletal muscles, adipose tissues, and the digestive, immune, or central nervous system. [4] However, this may only be the initial step in identifying the core mechanism shared by many pro-cachectic diseases, including pulmonary, cardiac, malignant, rheumatic, and renal disease. [5] With regard to cancer-associated cachexia, it was a pivotal step to achieve consensus about specific diagnostic and staging criteria. [6] Through that consensus report (CR), cancer cachexia can be easily diagnosed using a few anthropometric measurements and quick interview. Furthermore, the CR has taught that cachexia could develop not only in the terminal phase but also in the very early phase of the cancer trajectory. Cachexia can insidiously start and progress immediately after or even before the diagnosis of cancer. In addition, the CR proposed the development of a multimodal intervention by combining nutritional, physical, and psychosocial interventions. These framework and future direction of care possibly can greatly impact the designs and interventions of future clinical trials. However, the ultimate goal of cancer cachexia care and clinical trials remains to be elucidated. There are discrepancies in recognition of clinically relevant outcomes among researchers, pharmaceutical companies, and regulatory authorities. One of the newly developed ghrelin receptor agonists, anamorelin, has constantly been associated with a significant increase in lean body mass, weight, and appetite among patients with advanced nonsmall cell lung cancer (NSCLC) in two large-scale randomized phase III studies. [7] However, the drug was refused for marketing authorization by the European Medicines Agency (EMA) because of the potential risks outweigh the benefits. [8] The EMA concluded that the efficacy of anamorelin was not established because there was only a marginal effect on lean body mass and no reliable and clinically relevant effect on patient functioning or quality of life (QOL).
Therefore, there is an urgent need to reconsider the clinically relevant endpoints of clinical trials for cancer cachexia that simultaneously meet the demands from patients, researchers, and regulatory authorities. This review aimed to explore changes in designing clinical trials after the publication of the CR and discuss optimal patient-centered outcomes in future clinical trials for cancer cachexia.
Methods
Randomized controlled trials (RCTs) were identified by searching the PubMed using the following keywords: (cachexia [ (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) were classified as the pre-CR group, whereas those published within 8 years after the CR (2011-2018) were classified as the post-CR group. Entry criteria, the cachectic status of participants, concurrent treatments, and type of intervention were compared between the groups. Data on primary, secondary, and exploratory endpoints of each study were collected and compared between the groups.
Time-to-event curves were generated using the Kaplan-Meier method. Time-to-event was calculated as the time from the entry of the study to the date of the event, or last visit of the patients for whom the date of the event could not be confirmed. The database of a previous prospective observational study that recruited 60 elderly patients with newly diagnosed locally advanced or metastatic NSCLC who were to start chemotherapy and/or radiotherapy (trial registration no. UMIN000009768, [9] ) was used, in which the physical parameters of the patients such as weight, shuttle walking distance, and handgrip strength were regularly measured without any nutritional or exercise interventions. The event of cancer cachexia was defined as having ≥5% loss in the body weight within 6 months before participating in the study. The event of walking disturbance was defined as having a ≥10% decline in the incremental shuttle walking distance from the baseline value. The event of muscle weakness was defined as having ≥10% decline in handgrip strength from the baseline value. A disabling event was defined as having ≥10 points decline in the Barthel index from the baseline value.
Results

Overview of randomized controlled trials for cancer cachexia
A total of 65 RCT articles published between January 2003 and August 2018 were identified in PubMed; the reference list is shown in Supplementary Table 1 . Twenty-one trials comprised the pre-CR group, and 44 trials comprised the post-CR group [ Table 1 ]. According to the definitions in the CR, [6] 46 (71%) studies were designed to include patients with cancer cachexia. Among these studies, 12 (18%) potentially included patients with precachexia. Patients with refractory cachexia were excluded in most of the studies, while performance status or expected life expectancy was used as exclusion criteria. Approximately 19 (29%) studies recruited patients at risk for cachexia regardless of the presence of anorexia or weight loss. These were patients who underwent radiotherapy with or without chemotherapy for treatment of locally advanced head and neck, thoracic, or gynecological cancer, or patients with metastatic cancers who received palliative chemotherapy or care. In the post-CR group, the number of studies for patients with cachexia decreased, while that for patients with precachexia or patients at risk for cachexia increased.
With regard to cancer types and concurrent treatment modalities, most studies included a mixed population. After the CR, the proportion of studies for patients with specific cancer types receiving active cancer treatment was increasing. The major concurrent cancer treatments included palliative chemotherapy (20%) and radiotherapy with or without chemotherapy (15%). A total of 37 (57%) pharmacological interventions were tested, including single or combined use of omega-3 fatty acids, megestrol acetate, thalidomide, L-carnitine, anti-cytokines, nonsteroidal anti-inflammatory drugs, cannabinoids, ghrelin or its analogs, selective androgen receptor modulators, and others. Nonpharmacological interventions were tested in 28 (43%) studies, mostly in the post-CR group. Among these interventions, nutritional counseling with or without the use of oral nutritional supplements was the most common, and the proportion of studies involving such had doubled after the CR.
Common endpoints in randomized controlled trials for cancer cachexia
Endpoints tested in the listed studies are summarized in Table 2 . They were classified into eight components as follows: body mass, nutritional status, physical function, symptoms, QOL, prognosis, use of medical resources, (14) 6 (29) 3 (8) Palliative chemotherapy 13 (20) 3 (14) 10 (23) Radiotherapy ± chemotherapy 10 (15) 1 (5) 9 (23) Combined or not specified 33 (51) 11 (52) 22 (50) Type of intervention, n (%) Pharmacological 37 (57) 15 (71) 22 (50) ω3-PUFAs or fish oil 7 (11) 3 (14) 4 (9) Ghrelin or Ghrelin analogue 5 (8) 1 (5) 4 (9) Anti-TNF 3 (5) 3 (14) 0 Recently, assessments for walking capacity have been increasingly adopted as endpoints, including field walking tests, performance tests for the lower limbs, and physical activity measured by pedometers/accelerometers. Overall survival was selected as a prognostic indicator in 21 (32%) studies but rarely had positive results even in studies that showed improvements in weight or lean body mass. [10] [11] [12] Studies focusing on the use of medical resources have recently emerged (3 studies, 5%). Length of hospital stay and medical costs were assessed. [10, 13, 14] Moreover, the protective effects of interventions on the toxicity of radiotherapy or chemotherapy were assessed in several studies. Inflammatory and nutritional biomarkers were assessed in 25 (38%), and 21 (32%) studies and the major items were C-reactive protein, albumin, prealbumin, interleukin-6, and tumor necrosis factor-alpha.
Discussion
Functional prognosis and disability-free survival
The ultimate goal of care for cancer cachexia has not been established. The selection of endpoints, measuring scales, or statistical analysis varies with the hypothesis or preference of researchers, pharmaceutical companies, and regulatory authorities. [15] These variations in the selection of endpoints might decrease the comparability of the results of clinical trials and impede the development of effective treatment. Although concomitant improvement in skeletal muscle mass, physical function, QOL, and overall survival may be the ideal goal, these parameters do not always correlate with each other. For example, gain in lean body mass was not always associated with improvement in physical function [7, 11, [16] [17] [18] or QOL [11, 18, 19] among the listed studies.
This review proposes the model of the sequential relationship between physical events in patients with advanced lung cancer [ Figure 1 ]. This model was developed by the results of a previous prospective observational study that recruited elderly patients with advanced NSCLC. [9] In this aspect, sequential physical losses may begin early during cancer trajectory and continue until death. The earliest event among the patients was weight loss. More than half of the patients demonstrated ≥ 5% weight loss at Nutritional biomarkers included serum albumin, prealbumin, transferrin, hemoglobin, lymphocyte count, and others, p Inflammatory biomarkers included C-reactive protein, Glasgow prognostic score, cytokines and their receptors, and others, q Metabolic biomarkers included lipids, fatty acids, reactive oxygen species, bone metabolic markers, and others, the time of the study, suggesting that cachexia may start before the diagnosis of advanced cancer. In the following months, walking capacity and muscle strength declined. These physical losses finally resulted in disabling events, which were defined as a 10-point decrease in the Barthel index from baseline and occurred at a median of 13 months from baseline. The disability-free survival (DFS) curve occurred slightly below the overall survival curve with a slightly high-pitched slope. This study proposes DFS as a new measurable indicator of functional prognosis in cancer cachexia because disabling events reflect the multiple physical losses due to cancer cachexia and are independent of a death event. [20] Due to the advances in medical fields and changes in lifestyle, humans are now able to lead a physically vigorous life until shortly before the biologically fixed lifespan end. People increasingly wish for an active long life despite the presence or absence of incurable diseases. [21] DFS originally corresponds to the disability-free life expectancy in epidemiological studies. [22] Recently, DFS has been introduced as a relevant patient-centered outcome of clinical trials in the fields of perioperative, [23, 24] geriatric, [25] and pediatric medicine. [26] However, it is rarely selected as an endpoint of oncological clinical trials. A previous study reported that the presence of cancer cachexia at baseline was strongly associated with short DFS and long postdisability survival in elderly patients with advanced cancer. [27] In addition, this endpoint was associated with increased use of medical resources, including frequent unplanned visits, longer hospital stay, and higher cumulative medical costs. All of these measurements were considered important by their caregivers and healthcare providers.
Future direction of clinical trials for cancer cachexia
A new nonpharmacological multimodal intervention for cancer cachexia called the Nutrition and Exercise Treatment for Advanced Cancer (NEXTAC) program, is being developed. It combined nutritional counseling, low-intensity home-based resistance training, and promotive counseling of physical activity and was designed to prevent disability in elderly patients at risk for cachexia who are newly diagnosed with advanced NSCLC or pancreatic cancer and are to start systemic chemotherapy. Results of the Phase I feasibility study of this new intervention (NEXTAC-ONE) have been reported elsewhere. [28] A total of 30 participants showed excellent attendance (96.7%) and compliance for each intervention (≥90%) in the program, with only one dropout. The majority of patients was also adhered to the health education that was conducted and changed their health-related behavior such as increasing indoor or outdoor activity. [29] No severe adverse event occurred. Consequently, a prospective, multicenter, randomized Phase II clinical trial (NEXTAC-TWO, trial registration no. UMIN000028801) is being conducted to improve DFS in elderly patients with advanced cancer. A total of 130 patients are planned to be randomized to usual care or usual care plus NEXTAC in a 1:1 ratio. It was hypothesized that the NEXTAC prolongs 4 months of DFS from the usual care with 80% power. If this program could be proved to be both feasible and effective, it will be combined with newly emerging pharmacological interventions for cachexia to further improve functional prognosis and socioeconomic outcomes in elderly patients with advanced cancer.
Limitations
This review has several limitations. First, the literature search was carried out using only PubMed. A single reviewer (TN) carried out the selection of articles for inclusion. These drawbacks may result in a potential selection bias in the establishment of a reference list for RCTs. Second, not only the primary endpoint but also secondary and exploratory endpoints were included, without weighing the evidence that was shown in each study. Finally, the database used for the time-to-event curves included small samples from a single institution in Japan. Based on these limitations, we should pay careful attention while interpreting the results.
Conclusion
Clinical trials evaluating treatments for cancer cachexia are increasing. After the international consensus on the diagnostic and staging criteria for cancer cachexia, most clinical trials selected study populations in the earlier stage of the disease and the intervention tended to start earlier, concurrent with active cancer treatment. The true endpoint of these studies may be the expansion of active life with better QOL. Although the classical endpoint of increasing body mass would be an important outcome, it may not always contribute as a true endpoint. Thus, an optimal measurable endpoint should be identified, and a better combination of pharmacological and nonpharmacological interventions be established to improve functional prognosis in patients with this long-standing disease.
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